Company Interview / The Aussie small cap going global

Key points:

EZZ Life Sciences expands in South East Asia with a $21M distribution deal.US market entry with FDA-approved products, focusing on top-tier manufacturing.Strong financials: $19M cash balance, exploring further acquisitions.

Glenn Cross of EZZ Life Sciences (ASX: EZZ) shares the company's expansion plans. The company secures a $21 million, three-year deal with Roper Enterprises to distribute genomic health and wellness products in Thailand, Vietnam, and Singapore.

Glenn highlights the company's entry into the US market with FDA-approved products, leveraging top-tier manufacturing in LA under GMP. EZZ products debut on Amazon and direct-to-consumer models with strategic branding. EZZ Life Sciences also targets growth in China and South East Asia.

Glenn mentions EZZ's strong financials, revealing year-on-year revenue growth and a cash balance of $19 million. EZZ remains focused on expanding its global footprint and fortifying distribution through key partnerships in all major markets.